Sanofi has entered into a definitive agreement to acquire Blueprint Medicines Corporation. Sanofi is a publicly traded United States-based biopharmaceutical company specialising in systemic mastocytosis (SM) and other KIT-driven diseases.
The acquisition strengthens Sanofi’s rare disease and immunology portfolio, positioning it as a leader in targeted therapies for mast cell disorders.
Blueprint’s expertise in SM and its established presence among allergists, dermatologists, and immunologists will complement Sanofi’s existing immunology pipeline. This will expand its market reach and scientific capabilities.
The transaction includes Blueprint’s flagship drug, Ayvakit/Ayvakyt (avapritinib), the only approved treatment for advanced and indolent systemic mastocytosis (ASM & ISM) in the U.S. and European Union.
The acquisition also delivers elenestinib, a next-generation KIT D816V inhibitor in late-stage development, and BLU-808, a highly selective oral wild-type KIT inhibitor with potential applications across a broad range of immunological diseases.
These assets align with Sanofi’s strategic focus on rare immunological conditions and reinforce its commitment to developing innovative therapies.
Paul Hudson, CEO, Sanofi said: "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company. This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders. It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions. We are excited to welcome Blueprint’s talented people and we look forward to chasing the miracles of science together. This makes sense for science, for both companies, for healthcare professionals, and – most of all – for patients.”
Under the deal, Sanofi will pay US$129 per share in cash, valuing Blueprint at approximately $9.1 billion.
Additionally, Blueprint shareholders will receive a non-tradeable contingent value right (CVR), entitling them to milestone payments of $2 and $4 per CVR upon achieving regulatory and development milestones for BLU-808.
Kate Haviland, CEO, Blueprint Medicines said: “Since our founding, Blueprint Medicines has worked at the intersection of scientific innovation and operational excellence. I’m incredibly proud of the medical innovations our people have created and delivered to patients. We have translated our unique scientific understanding of mast cell biology into a portfolio of important therapies including Ayvakit – the first and only medicine 1/5 approved to treat the root cause of systemic mastocytosis – and worked collaboratively with communities to improve standards of care and patient outcomes. With this agreement, we begin our next chapter with Sanofi, whose exceptional leadership in rare disease and immunology and proven ability to solve medical challenges at scale stand to accelerate our joint mission to bring life-changing medicines to many more patients around the world.”
The total equity value of the transaction, including potential CVR payouts, amounts to approximately US$9.5 billion (A$14.42 billion) on a fully diluted basis.
The acquisition is expected to close in Q3 of 2025, pending shareholder and regulatory approvals.
At the time of writing, the share price of Sanofi SA (EPA: SAN) was €85.91, down €1.61 (1.84%) today, with a market cap of around €106.84 billion. Meanwhile, Blueprint Medicines Corp's share price (NASDAQ: BPMC) was US$127.79, up $26.44 (26.09%) today, with a market cap of approximately US$8.25 billion.
